Michael Grippo - Catalent Insider
CTLT Stock | USD 54.96 0.68 1.25% |
Insider
Michael Grippo is Senior Vice President - Strategy and Corporate Development of Catalent since 2019.
Age | 55 |
Tenure | 5 years |
Address | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 |
Phone | 732 537 6200 |
Web | https://www.catalent.com |
Catalent Management Efficiency
Return On Tangible Assets is likely to gain to -0.03 in 2024. Return On Capital Employed is likely to gain to -0.02 in 2024. At this time, Catalent's Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 157.5 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 6.2 B in 2024. Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 9 records | INSIDER Age | ||
Buddy Wilson | Grown Rogue International | N/A | |
Ryan Kee | Grown Rogue International | 40 | |
Adam August | Grown Rogue International | 45 | |
Sonny Newman | C21 Investments | N/A | |
Obie Strickler | Grown Rogue International | 40 | |
Feng Zhou | China SXT Pharmaceuticals | 32 | |
Steven Lightman | Grown Rogue International | 66 | |
Xiaodong Pan | China SXT Pharmaceuticals | 46 | |
Eric Shoemaker | C21 Investments | N/A |
Management Performance
Return On Equity | -0.28 | ||||
Return On Asset | -0.0071 |
Catalent Leadership Team
Elected by the shareholders, the Catalent's board of directors comprises two types of representatives: Catalent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalent. The board's role is to monitor Catalent's management team and ensure that shareholders' interests are well served. Catalent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalent's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Castellano, VP of Fin. and Investor Relations and Treasurer | ||
Paul Surdez, Vice Relations | ||
Joseph JD, General VP | ||
Peter Zippelius, Independent Director | ||
Steven Fasman, Senior Vice President General Counsel and Corporate Secretary | ||
Michael Hatzfeld, VP Officer | ||
Kay Schmidt, Senior Vice President - Technical Operations | ||
Karen Santiago, VP Office | ||
Jonathan Arnold, President - Oral & Specialty Delivery | ||
Ricky Hopson, Division President | ||
John MBA, Executive Board | ||
John Chiminski, Chairman of the Board, Chief Executive Officer | ||
Donald Morel, Independent Director | ||
John Greisch, Independent Director | ||
Gregory Lucier, Independent Director | ||
Rolf Classon, Independent Director | ||
Michael Barber, Independent Director | ||
Steven Esq, Corp VP | ||
Karen Flynn, President - Biologics and Chief Commercial Officer | ||
Michael Grippo, Senior Vice President - Strategy and Corporate Development | ||
Matti Masanovich, Senior CFO | ||
Julien Meissonnier, VP Officer | ||
Christa Kreuzburg, Independent Director | ||
Lisa Evoli, Senior Officer | ||
Madhavan Balachandran, Independent Director | ||
J Carroll, Independent Director | ||
Scott Gunther, Senior Vice President - Quality & Regulatory Affairs | ||
Wetteny Joseph, Chief Financial Officer, Senior Vice President | ||
Alessandro Maselli, Senior Vice President - Global Operations | ||
Ricci Whitlow, President - Clinical Supply Services | ||
Charles Lickfold, Senior Vice President, Chief Information Officer | ||
Aristippos Gennadios, President - Softgel & Oral Technologies | ||
Ricardo Pravda, Chief Human Resource Officer, Senior Vice President | ||
Jack Stahl, Lead Independent Director | ||
Z Mahdavi, Vice President of Open Innovation, Biologics, Cell and Gene Therapy | ||
Rosemary Crane, Independent Director |
Catalent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.28 | ||||
Return On Asset | -0.0071 | ||||
Profit Margin | (0.28) % | ||||
Operating Margin | 0.01 % | ||||
Current Valuation | 14.65 B | ||||
Shares Outstanding | 180.98 M | ||||
Shares Owned By Insiders | 0.50 % | ||||
Shares Owned By Institutions | 98.08 % | ||||
Number Of Shares Shorted | 6.8 M | ||||
Price To Earning | 17.80 X |
Pair Trading with Catalent
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalent position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalent will appreciate offsetting losses from the drop in the long position's value.Moving against Catalent Stock
The ability to find closely correlated positions to Catalent could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalent when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalent - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalent to buy it.
The correlation of Catalent is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalent moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalent moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Catalent can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Catalent Stock Analysis
When running Catalent's price analysis, check to measure Catalent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalent is operating at the current time. Most of Catalent's value examination focuses on studying past and present price action to predict the probability of Catalent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalent's price. Additionally, you may evaluate how the addition of Catalent to your portfolios can decrease your overall portfolio volatility.